Atterocor is a drug development company focused on novel therapies for adrenal cancer. The Company launched in 2012 with a Series A financing led by top-tier life sciences investors Frazier Healthcare and 5AM Ventures. Atterocor is based in Ann Arbor, Michigan.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/03/12 | $16,000,000 | Series A |
5AM Ventures Frazier Healthcare | undisclosed |
